Evidence map›Paper›PMID 29294239›Full record

ArticleNeurotoxicity research2019

KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity.

Luis Arturo Fonseca-Fonseca, Yanier Nuñez-Figueredo, Jeney Ramírez Sánchez, Maylin Wong Guerra, Estael Ochoa-Rodríguez, Yamila Verdecia-Reyes, René Delgado Hernádez, Noelio J Menezes-Filho, Teresa Cristina Silva Costa, Wagno Alcântara de Santana and 4 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Luis Arturo Fonseca-FonsecaCentro de Investigación y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600, Ciudad de la Habana, Cuba.
Yanier Nuñez-FigueredoCentro de Investigación y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600, Ciudad de la Habana, Cuba.
Jeney Ramírez SánchezCentro de Investigación y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600, Ciudad de la Habana, Cuba.
Maylin Wong GuerraCentro de Investigación y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600, Ciudad de la Habana, Cuba.
Estael Ochoa-RodríguezLaboratorio de Síntesis Orgánica. Departamento de Química Orgánica. Facultad de Química, Universidad de La Habana (Zapata s/n entre G y Carlitos Aguirre, Vedado, Plaza de la Revolución, CP 10400, Ciudad de la Habana, Cuba.
Yamila Verdecia-ReyesLaboratorio de Síntesis Orgánica. Departamento de Química Orgánica. Facultad de Química, Universidad de La Habana (Zapata s/n entre G y Carlitos Aguirre, Vedado, Plaza de la Revolución, CP 10400, Ciudad de la Habana, Cuba.
René Delgado HernádezCentro de Investigación y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600, Ciudad de la Habana, Cuba.
Noelio J Menezes-FilhoLaboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon s/n, Vale do Canela, Salvador, Bahia, CEP 41100-100, Brazil.
Teresa Cristina Silva CostaLaboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon s/n, Vale do Canela, Salvador, Bahia, CEP 41100-100, Brazil.
Wagno Alcântara de SantanaLaboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon s/n, Vale do Canela, Salvador, Bahia, CEP 41100-100, Brazil.
Joana L OliveiraLaboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon s/n, Vale do Canela, Salvador, Bahia, CEP 41100-100, Brazil.
Juan Segura-AguilarMolecular & Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.
Victor Diogenes Amaral da SilvaLaboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon s/n, Vale do Canela, Salvador, Bahia, CEP 41100-100, Brazil.
Silva Lima CostaLaboratório de Neuroquímica e Biologia Celular, Instituto de Ciências da Saúde, Universidade Federal da Bahia - UFBA, Av. Reitor Miguel Calmon s/n, Vale do Canela, Salvador, Bahia, CEP 41100-100, Brazil. costasl@ufba.br.
Universidade Federal da Bahia · BRCentro de Investigación y Desarrollo de medicamentosCentro de Aplicaciones Tecnológicas y Desarrollo Nuclear · CUUniversity of Havana · CUUniversity of Chile · CL

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 09-061Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (BR) 178/122
6 · The paper itself

Abstract

The etiology of Parkinson's disease is not completely understood and is believed to be multifactorial. Neuronal disorders associated to oxidative stress and mitochondrial dysfunction are widely considered major consequences. The aim of this study was to investigate the effect of the synthetic arylidenmalonate derivative 5-(3,4-dihydroxybenzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (KM-34), in oxidative stress and mitochondrial dysfunction induced by 6-hydroxydopamine (6-OHDA). Pretreatment (2 h) with KM-34 (1 and 10 μM) markedly attenuated 6-OHDA-induced PC12 cell death in a concentration-dependent manner. KM-34 also inhibited H

Indexed as

AnimalsAntioxidantsCatecholsDose-Response Relationship, DrugMaleMitochondriaNeuroprotective AgentsOxidative StressOxidopamineParkinsonian DisordersPC12 CellsRatsRats, Wistar5-(3, 4-dydroxyl-benzylidene)-2, 2-dimethyl-1, 3-dioxane-4, 6-dioneAntioxidantsCatecholsNeuroprotective AgentsOxidopamineArylidenmalonate derivedKM-34MitochondriaNeuroprotectionParkinson’s disease

Identifiers

PMID29294239
OpenAlexW2781743065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.